EMAIL TO A COLLEAGUE COMMENT

 

Two-Drug Combination to Treat Thyroid Cancer


On May 4, 2018, the FDA granted approval to Novartis Pharmaceuticals Corporation to market Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic), and has a type of abnormal gene, BRAF V600E (BRAF V600E mutation-positive).

 

“This is the first FDA-approved treatment for patients with this aggressive form of thyroid cancer, and the third cancer with this specific gene mutation that this drug combination has been approved to treat,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “This approval demonstrates that targeting the same molecular pathway in diverse diseases is an effective way to expedite the development of treatments that may help more patients.”

 

Thyroid cancer is a disease in which cancer cells form in the tissues of the thyroid gland. Anaplastic thyroid cancer is a rare, aggressive type of thyroid cancer. The National Institutes of Health estimates there will be 53,990 new cases of thyroid cancer and an estimated 2,060 deaths from the disease in the United States in 2018. Anaplastic thyroid cancer accounts for about 1 to 2 percent of all thyroid cancers.

 

Both Tafinlar and Mekinist are also approved for use, alone or in combination, to treat BRAF V600 mutation-positive metastatic melanoma. Additionally, Tafinlar and Mekinist are approved for use, in combination, to treat BRAF V600E mutation-positive, metastatic non-small cell lung cancer.

 

The efficacy of Tafinlar and Mekinist in treating anaplastic thyroid cancer (ATC) was shown in an open-label clinical trial of patients with rare cancers with the BRAF V600E mutation. The trial measured the percent of patients with a complete or partial reduction in tumor size (overall response rate). Of 23 evaluable patients, 57 percent experienced a partial response and 4 percent experienced a complete response; in nine (64 percent) of the 14 patients with responses, there were no significant tumor growths for six months or longer.

 

The side effects of Tafinlar and Mekinist in patients with ATC are consistent with those seen in other cancers when the two drugs are used together. Common side effects include fever (pyrexia), rash, chills, headache, joint pain (arthralgia), cough, fatigue, nausea, vomiting, diarrhea, muscle pain (myalgia), dry skin, decreased appetite, edema, hemorrhage, high blood pressure (hypertension), and difficulty breathing (dyspnea).

 

Severe side effects of Tafinlar include the development of new cancers, growth of tumors in patients with BRAF wild-type tumors, serious bleeding problems, heart problems, severe eye problems, fever that may be severe, serious skin reactions, high blood sugar or worsening diabetes, and serious anemia.

 

Severe side effects of Mekinist include the development of new cancers; serious bleeding problems; inflammation of intestines and perforation of the intestines; blood clots in the arms, legs, or lungs; heart problems; severe eye problems; lung or breathing problems; fever that may be severe; serious skin reactions; and high blood sugar or worsening diabetes.

 

Both Tafinlar and Mekinist can cause harm to a developing fetus. Women should be advised of the potential risk to the fetus and to use effective contraception.

 

See the FDA Announcement

 

See also Medical Law Perspectives Report: Malpractice or Negligence Liability: Thyroid Disorders and Conditions

 

See also Medical Law Perspectives Report: Chemotherapy: Risks and Liabilities When the Treatment Is Toxic 

 

See also Medical Law Perspectives Report: Unlocking Genetic Secrets: Liability Risks for Genetic Testing and Information Providers 

 

See also Medical Law Perspectives Report: More Than Skin Deep: Skin Cancer Misdiagnosis and Other Liability Issues 

 

See also Medical Law Perspectives Report: Mistakes in Diagnosing Cancer: Liability Concerns for Misdiagnosis, Failure to Diagnose, and Delayed Diagnosis 

 

See the Medical Law Perspectives Blog: Failure to Diagnose Cancer Claims Face Hurdles, Especially in New York

 

 

REPRINTS & PERMISSIONS COMMENT